{
    "nct_id": "NCT06800092",
    "official_title": "Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment",
    "inclusion_criteria": "* Female\n* Ages 30 - 50 years\n* Self-reported menses occurrence within past 12 months\n* Diagnosis of ER+/HER2- breast cancer\n* Willing and able to comply with study procedures\n* Willing and able to provide consent\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 30 Years\nMust have maximum age of 50 Years",
    "exclusion_criteria": "* Untreated thyroid disorder\n* Untreated diabetes\n* BMI >30\n* Current treatment with metformin\n* Diagnosed neuromuscular disease\n* Diagnosed neurovascular disease\n* Prior history of cognitive impairment\n* Prior history of chemotherapy treatment\n* HIV, Hepatitis B or Hepatitis C\n* Systolic blood pressure <90 or >170, diastolic blood pressure <50 or >110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (>90/50 and <170/110)\n* Use of alpha blockers in the past 2 weeks\n* Use of PDE5 inhibitors in the past 2 weeks\n* Use of nitrates\n* Subjects with MRI incompatible devices\n* Subjects with severe claustrophobia\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation",
    "miscellaneous_criteria": ""
}